Precigen ActoBio Announces Positive Topline Results from Phase 1b Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes
Go back to Precigen ActoBio Announces Positive Topline Results from Phase 1b Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes| (NASDAQ: PGEN) | Delayed: 5.36 -0.02 (0.37%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.38 | 52 Week High | $ | |||
| Open | $5.29 | 52 Week Low | $ | |||
| Day High | $5.59 | P/E | N/A | |||
| Day Low | $5.27 | EPS | $ | |||
| Volume | 5,246,902 | |||||
